IL18R1 and myositis disease: In myositis, this could lead to the use of additional more targeted biologic agents, in addition to the current strategies of autoantibody depletion (e.g., rituximab, intravenous immunoglobulin) and targeting of a common cytokine receptor signaling pathway (e.g., Janus kinase inhibitors)[4].